Why Eli Lilly Stock Was Looking Sickly Today
Investors were spooked by a peer's notable reduction in sales and profitability guidance.
This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity.
10 stocks we like better than Eli Lilly ›
One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly (NYSE: LLY) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether S&P 500 index. That decline wasn't necessarily Eli Lilly's fault, though.
Reducing weight, reducing guidance
Eli Lilly's recent popularity is due in no small measure to its plunge into the highly lucrative weight-loss drug market. In late 2023, its Zepbound -- essentially the same treatment as its diabetes drug Mounjaro -- was approved to treat obesity, and the company was off to the races.
On Tuesday, though, the standard-bearer for the segment took quite a tumble. That was Novo Nordisk, which this morning lowered its guidance for both full-year sales and operating profit.
The growth forecast for the former was reduced to 8% to 14% over the 2024 tally (previous guidance range: 13% to 21%). Ditto for operating profit, which is now expected to rise in a range of 10% to 16%. That would be encouraging, if it weren't for the fact that management's preceding prediction was 16% to 24%.
Novo Nordisk is known for developing and selling Wegovy, the first GLP-1 drug approved by the U.S. Food and Drug Administration specifically for weight loss. The company has flown to renown and admiration on the wings of that drug, which remains a key product. Investors probably fear that Eli Lilly's Zepbound will also perform worse than expected.
Not an emergency
I don't think anyone should push the panic button on Eli Lilly due to this (or Novo Nordisk, while I'm at it). Demand for obesity drugs remains strong and nearly unlimited, so both Zepbound and Wegovy -- which still benefit from a lack of competitors, at least for now -- should continue to be growth drivers.
Also, in the case of Eli Lilly, the sprawling pharmaceutical company has a vast portfolio and a very wide development pipeline, so it's hardly dependent on one drug -- no matter how currently popular that drug might be.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!*
Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Why Eli Lilly Stock Was Looking Sickly Today was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
[Latest] Global Paracetamol Market Size/Share Worth USD 1460.23 Million by 2034 at a 5.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Paracetamol Market size & share revenue was valued at approximately USD 876.48 Million in 2024 and is expected to reach USD 922.41 Million in 2025 and is expected to reach around USD 1460.23 Million by 2034, at a CAGR of 5.24% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Aspen Pharmacare, Adcock Ingram, Julphar (Gulf Pharmaceutical Industries), Ache Laboratories Pharmaceutics, EMS Pharma, Hikma Pharmaceuticals, Bharat Chemicals, Farmson Pharmaceuticals, SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Mylan N.V. (now part of Viatris) and others. Austin, TX, USA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Paracetamol Market Size, Trends and Insights By Product Type (Tablet, Capsule, Liquid Suspension, Powder), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application Type (Headache & Fever, Muscle Cramps, Cold & Cough), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of the global Paracetamol Market size & share was valued at approximately USD 876.48 Million in 2024 and is expected to reach USD 922.41 Million in 2025 and is expected to reach a value of around USD 1460.23 Million by 2034, at a compound annual growth rate (CAGR) of about 5.24% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Paracetamol Market @ Overview As per the industry experts at CMI, the paracetamol market is expected to witness a linear CAGR during the forecast period. This could be attributed to steadiness on the part of demand for paracetamol globally. Paracetamol is being used as an antipyretic and analgesic, especially in fever and pain relief medications. The market is further catalyzed by growing healthcare awareness, increasing incidences of chronic conditions, and a rising aging population worldwide. Key Trends & Drivers Growing Incidences of Fever and Pain to Determine Growth: Ailments such as flu, headaches, arthritis, and post-operative pain are reported to be managed using paracetamol. Rising incidences on their part do directly translate into a higher demand for medication. The consumers are also increasingly developing awareness about OTC medications such as paracetamol and do prefer treating minor illnesses on their own, thereby driving its usage further. Request a Customized Copy of the Paracetamol Market Report @ Increased Usage in Surgical Applications to Catalyze the Paracetamol Market: IV paracetamol is increasingly preferred due to its ability to effectively manage moderate to severe pain without side effects linked with opioids, such as constipation and nausea. It makes provision for quicker pain relief in comparison with oral medications, thereby making it the most sought-after medication post-surgery. Report Scope Feature of the Report Details Market Size in 2025 USD 922.41 Million Projected Market Size in 2034 USD 1460.23 Million Market Size in 2024 USD 876.48 Million CAGR Growth Rate 5.24% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Product Type, Distribution Channel, Application Type and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Paracetamol report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Paracetamol report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Paracetamol Market Report @ SWOT Analysis Strengths: Paracetamol is easily accessible OTC in various forms such as capsules, tablets, and liquids. It is comparatively inexpensive, thereby rendering it cost-effective for a wider consumer base. Plus, it is one of the common ingredients in various fever-reducing and pain relief products and is used for treating conditions such as muscle aches, headaches, and the common cold. Rising occurrences of lifestyle-oriented ailments are the catalysts to paracetamol market. Weaknesses: Improper dosage or overuse could cause damage to the liver. Additionally, the reliance of the market on API production in certain regions is likely to create vulnerabilities pertaining to the supply chain. Furthermore, the market is bound to face fierce competition from the manufacturers of generic medicines, which could reduce the market share of established players and reduce their overall profitability. Opportunities: Researching and developing paracetamol-based products for specified pain conditions such as migraines are likely to unlock novel market segments. Also, exploration of the use of paracetamol in conjunction with the other drugs for improved pain relief and the other therapeutic advantages could provide lucrative opportunities to the paracetamol market. Threats: Negative publicity around the safety concerns related to paracetamol is likely to negatively affect the consumers' demand and perception. Also, Volatility of costs of raw materials used in the production of paracetamol could adversely affect profitability and production costs. Emergence of newer combinations of pain management solutions could also cut down on market share. Request a Customized Copy of the Paracetamol Market Report @ Key questions answered in this report: What is the size of the Paracetamol market and what is its expected growth rate? What are the primary driving factors that push the Paracetamol market forward? What are the Paracetamol Industry's top companies? What are the different categories that the Paracetamol Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Paracetamol market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Paracetamol Research Report | Fast Delivery Available - [220+ Pages] @ Regional Perspective The paracetamol market is divided into North America, Europe, Asia Pacific, and LAMEA. North America North America leads the paracetamol market, and the status quo is expected to remain unchanged during the forecast period. This is credited to rising incidences of migraines, headaches, and fever all across the U.S. The American Migraine Foundation states that the year 2020 witnessed the presence of over 4 million adults in the U.S. battling chronic daily migraine, that too, with close to 15 headaches per month. The government is also handsomely investing in research regarding therapeutics for chronic pain. As per the May 2022 update from the NIH (National Institute of Health), the government of the U.S. did spend USD 689 Million and USD 725 Million in 2020 and 2021 respectively in this regard. Europe Europe is expected to hold a significant share of the paracetamol market owing to an increase in healthcare spending on the part of the governments. The tropical regions are prone to year-round influenza, which is fueling the market therein. The EU has set stringent regulatory standards for various pharmaceuticals (inclusive of paracetamol), which ascertain safety and quality. Asia Pacific Asia Pacific is expected to witness the highest CAGR in the paracetamol market during the forecast period. This could be due to a rise in the population suffering from the common cold, cough, fever, and migraine. China and India are the major manufacturers of paracetamol APIs. They are thus paving the way for cost-effective supply chains. LAMEA Individuals in LAMEA are gaining more awareness regarding the advantages of self-treating the minor ailments with OTC medications such as paracetamol, thereby resulting in a higher rate of consumption. Increase in accessibility of e-Commerce platforms and online pharmacies is making it simpler for the consumers based in LAMEA to buy paracetamol, thereby boosting the market further. Request a Customized Copy of the Paracetamol Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'Paracetamol Market Size, Trends and Insights By Product Type (Tablet, Capsule, Liquid Suspension, Powder), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application Type (Headache & Fever, Muscle Cramps, Cold & Cough), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Paracetamol Market: Johnson & Johnson GlaxoSmithKline Pfizer Inc. Novartis AG Reddy's Laboratories Ltd. Aspen Pharmacare Adcock Ingram Julphar (Gulf Pharmaceutical Industries) Ache Laboratories Pharmaceutics EMS Pharma Hikma Pharmaceuticals Bharat Chemicals Farmson Pharmaceuticals SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation) Mylan N.V. (now part of Viatris) Others Click Here to Access a Free Sample Report of the Global Paracetamol Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: US Surgical Instrument Tracking System Market: US Surgical Instrument Tracking Market Size, Trends and Insights By Technology (Barcodes, RFID), By Application (Hardware, Software, Services), By End-use (Hospitals, Ambulatory Surgical Centers), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025-2034 Digital Mammography Market: Digital Mammography Market Size, Trends and Insights By Technology (2D Full Field Digital Mammography, 3D Full Field Digital Mammography (Digital Breast Tomosynthesis), Contrast Enhanced Digital Mammography), By Product Type (Digital Mammography System, Display Unit, Central Processing Units, Visualization Software), By End-user (Hospitals and Surgical Centers, Breast Care Centers, Diagnostic Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Lenacapavir Injection Market: Lenacapavir Injection Market Size, Trends and Insights By Indication (HIV Treatment, Pre-Exposure Prophylaxis (PrEP)), By Formulation (Injectable, Oral Tablets), By Distribution Channel (Branded Medicine, Generic Medicine), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Pharmaceutical Metal Detector Market: Pharmaceutical Metal Detector Market Size, Trends and Insights By Technology (Magnetic Field Detectors, Multi-frequency Detectors, X-Ray Inspection with Metal Detectors), By Application (Quality Control, Contaminant Detection, Packaging, Compliance), By End-user (Pharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs), Biopharmaceutical Companies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Deep Eutectic Solvents Market: Deep Eutectic Solvents Market Size, Trends and Insights By Product (Organic Salts + Metal Salts, Organic Salts + Metal Hydrates, Organic Salts + Hydrogen Bond Donor, Metal Chlorides + Hydrogen Bond Donor), By End-use (Pharmaceuticals & Healthcare, Food & Beverages Processing, Cosmetics & Personal Care, Chemical & Materials Industry), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025-2034 Medical Equipment Calibration Services Market: Medical Equipment Calibration Services Market Size, Trends and Insights By Service (In-house, Third-party Services, Original Equipment Manufacturers (OEMs)), By End-use (Hospitals, Clinical Laboratories), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 CRISPR and Cas Genes Market: CRISPR and Cas Genes Market Size, Trends and Insights By Technology Type (CRISPR/Cas9, CRISPR/Cas13, CRISPR/Cas14, Others), By Delivery Method (Ex vivo, In vivo, Physical Methods, Others), By Application Area (Functional Genomics, Oncology, Infectious Diseases, Others), By Tool Type (Guide RNA, CRISPR Plasmids, Cas Nucleases, Custom CRISPR Libraries, Vectors & Cloning Kits), By Crop Type (Cereals & Grains, Fruits & Vegetables, Oilseeds & Pulses, Industrial Crops), By Disease Type (Cancer, Blood Disorders, Ophthalmic Diseases, Infectious Diseases, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Y Chromosome Microdeletion Detection Kit Market: Y Chromosome Microdeletion Detection Kit Market Size, Trends and Insights By Product Type (PCR-based Kits, FISH-based Kits, Others), By Application (Hospitals, Diagnostic Laboratories, Research Institutes, Others), By End-User (Healthcare Providers, Research Laboratories, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 The Paracetamol Market is segmented as follows: By Product Type Tablet Capsule Liquid Suspension Powder By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies By Application Type Headache & Fever Muscle Cramps Cold & Cough Click Here to Get a Free Sample Report of the Global Paracetamol Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Paracetamol Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Paracetamol Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Paracetamol Market? What Was the Capacity, Production Value, Cost and PROFIT of the Paracetamol Market? What Is the Current Market Status of the Paracetamol Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Paracetamol Market by Considering Applications and Types? What Are Projections of the Global Paracetamol Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Paracetamol Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Paracetamol Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Paracetamol Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Paracetamol Industry? Click Here to Access a Free Sample Report of the Global Paracetamol Market @ Reasons to Purchase Paracetamol Market Report Paracetamol Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Paracetamol Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Paracetamol Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Paracetamol Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Paracetamol market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Paracetamol Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Paracetamol market analysis. The competitive environment of current and potential participants in the Paracetamol market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Paracetamol market should find this report useful. The research will be useful to all market participants in the Paracetamol industry. Managers in the Paracetamol sector are interested in publishing up-to-date and projected data about the worldwide Paracetamol market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Paracetamol products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Paracetamol Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Paracetamol Research Report | Fast Delivery Available - [220+ Pages] @ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
27 minutes ago
- Business Wire
American Water Announces Pricing of Common Stock Offering of 7,042,254 Shares with a Forward Component
BUSINESS WIRE)--American Water Works Company, Inc. (NYSE: AWK) announced today the pricing of a registered underwritten offering of 7,042,254 shares of its common stock at a price to public of $142.00 per share. Subject to certain conditions, all shares are expected to be borrowed by the forward purchasers (as defined below) (or their respective affiliates) from third parties and sold to the underwriters and offered in connection with the forward sale agreements described below. Wells Fargo Securities, J.P. Morgan, and Mizuho are acting as joint book-running managers and as representatives of the underwriters for the offering. In connection with this offering, American Water will issue and sell shares to the underwriters to the extent that the forward purchasers (or their respective affiliates) do not borrow and sell such number of shares. In connection with the offering, American Water entered into forward sale agreements with Wells Fargo Bank, National Association, JPMorgan Chase Bank, National Association and Mizuho Markets Americas LLC (or their respective affiliates), each in its capacity as a forward counterparty (the 'forward purchasers'), pursuant to which American Water agreed to issue and sell to the forward purchasers (subject to American Water's right to elect cash settlement or net share settlement under the forward sale agreements) an aggregate of 7,042,254 shares of its common stock. American Water granted the underwriters a 30-day option to purchase up to an additional 1,056,338 shares of its common stock on the same terms as this offering. If the underwriters exercise their option to purchase additional shares of common stock, American Water expects to enter into additional forward sale agreements with the forward purchasers with respect to the additional shares. In connection with the forward sale agreements, the forward purchasers (or affiliates thereof) are expected to borrow from third-party lenders and sell to the underwriters all of the shares of American Water's common stock to be sold in this offering. The offering is expected to close on August 6, 2025. American Water will not receive any proceeds from the sale of the common stock sold by the forward purchasers to the underwriters. Settlement of the forward sale agreements is expected to occur on or prior to December 31, 2026, and American Water will use any net cash proceeds that it receives upon settlement of the forward sale agreements for general corporate purposes. The offering is being made pursuant to American Water's effective shelf registration statement filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, and no offer, solicitation or sale of any securities shall be made, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offering of these securities will be made only by means of a prospectus and a related prospectus supplement meeting the requirements of Section 10 of the Securities Act of 1933. The prospectus supplement and the accompanying prospectus related to the offering will be available on the SEC's website at A copy of the prospectus supplement and the accompanying prospectus with respect to this offering may be obtained from American Water or from (i) Wells Fargo Securities, by mail to Wells Fargo Securities, 90 South 7 th Street, 5 th Floor, Minneapolis, MN 55402, by email at WFScustomerservice@ or by telephone at (800) 645-3751 (option #5), (ii) J.P. Morgan, by mail to J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email: prospectus-eq_fi@ and postsalemanualrequests@ or (iii) Mizuho, by mail to Mizuho Securities USA LLC, 1271 Avenue of the Americas, 3 rd Floor, New York, NY 10020, Attention: Equity Capital Markets, by email at US-ECM@ or by telephone at (212) 205-7600. About American Water American Water (NYSE: AWK), headquartered in Camden, New Jersey, is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, American Water employs approximately 6,700 professionals who provide drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. Cautionary Statement Concerning Forward-Looking Statements Certain statements in this press release including, without limitation, with respect to the public offering of American Water's securities and the intended use of proceeds, are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. In some cases, these forward-looking statements can be identified by words with prospective meanings such as 'intend,' 'plan,' 'estimate,' 'believe,' 'anticipate,' 'expect,' 'predict,' 'project,' 'propose,' 'assume,' 'forecast,' 'likely,' 'uncertain,' 'outlook,' 'future,' 'pending,' 'goal,' 'objective,' 'potential,' 'continue,' 'seek to,' 'may,' 'can,' 'should,' 'will' and 'could' or the negative of such terms or other variations or similar expressions. These forward-looking statements are predictions based on American Water's current expectations and assumptions regarding future events. They are not guarantees or assurances of any outcomes, financial results of levels of activity, performance or achievements, and readers are cautioned not to place undue reliance upon them. The forward-looking statements are subject to a number of estimates and assumptions, and known and unknown risks, uncertainties and other factors. Actual results may differ materially from those discussed in the forward-looking statements included in this press release as a result of the factors discussed in American Water's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC, and because of factors such as: the decisions of governmental and regulatory bodies, including decisions to raise or lower customer rates; the timeliness and outcome of regulatory commissions' and other authorities' actions concerning rates, capital structure, authorized return on equity, capital investment, system acquisitions and dispositions, taxes, permitting, water supply and management, and other decisions; changes in customer demand for, and patterns of use of, water and energy, such as may result from conservation efforts, or otherwise; limitations on the availability of American Water's water supplies or sources of water, or restrictions on its use thereof, resulting from allocation rights, governmental or regulatory requirements and restrictions, drought, overuse or other factors; a loss of one or more large industrial or commercial customers due to adverse economic conditions, or other factors; present and future proposed changes in laws, governmental regulations and policies, including with respect to the environment (such as, for example, potential improvements or changes to existing Federal regulations with respect to lead and copper service lines and galvanized steel pipe), health and safety, data and consumer privacy, security and protection, water quality and water quality accountability, contaminants of emerging concern (including without limitation per- and polyfluoroalkyl substances (collectively, 'PFAS')), public utility and tax regulations and policies, and impacts resulting from U.S., state and local elections and changes in federal, state and local executive administrations; American Water's ability to collect, distribute, use, secure and store consumer data in compliance with current or future governmental laws, regulations and policies with respect to data and consumer privacy, security and protection; weather conditions and events, climate variability patterns, and natural disasters, including drought or abnormally high rainfall, prolonged and abnormal ice or freezing conditions, strong winds, coastal and intercoastal flooding, pandemics and epidemics, earthquakes, landslides, hurricanes, tornadoes, wildfires, electrical storms, sinkholes and solar flares; the outcome of litigation and similar governmental and regulatory proceedings, investigations or actions; the risks associated with American Water's aging infrastructure, and its ability to appropriately improve the resiliency of or maintain, update, redesign and/or replace, current or future infrastructure and systems, including its technology and other assets, and manage the expansion of its businesses; exposure or infiltration of American Water's technology and critical infrastructure systems, including the disclosure of sensitive, personal or confidential information contained therein, through physical or cyber attacks or other means, and impacts from required or voluntary public and other disclosures, as well as civil class action and other litigation or legal, regulatory or administrative proceedings, related thereto; American Water's ability to obtain permits and other approvals for projects and construction, update, redesign and/or replacement of various water and wastewater facilities; changes in American Water's capital requirements; American Water's ability to control operating expenses and to achieve operating efficiencies, and American Water's ability to create, maintain and promote initiatives and programs that support the affordability of its regulated utility services; the intentional or unintentional actions of a third party, including contamination of American Water's water supplies or the water provided to its customers; American Water's ability to obtain and have delivered adequate and cost-effective supplies of pipe, equipment (including personal protective equipment), chemicals, power and other fuel, water and other raw materials, and to address or mitigate supply chain constraints that may result in delays or shortages in, as well as increased costs of, supplies, products and materials that are critical to or used in American Water's business operations; American Water's ability to successfully meet its operational growth projections, either individually or in the aggregate, and capitalize on growth opportunities, including, among other things, with respect to: acquiring, closing and successfully integrating regulated operations, including without limitation its ability to (i) obtain required regulatory approvals for such acquisitions, (ii) prevail in litigation or other challenges related to such acquisitions, and (iii) recover in rates the fair value of assets of the acquired regulated operations; American Water's Military Services Group entering into new military installation contracts, price redeterminations, and other agreements and contracts, with the U.S. government; and realizing anticipated benefits and synergies from new acquisitions; in addition to the foregoing, various risks and uncertainties associated with the agreement to acquire certain water and wastewater systems from a subsidiary of Nexus Water Group, Inc., including: (i) the final amount of the rate base to be acquired, and the amount of post-closing adjustments to the purchase price, if any, as contemplated by the acquisition agreement; (ii) the various impacts and effects of (a) compliance, or attempted compliance with, the terms and conditions of the acquisition agreement, and/or (b) the completion of or, or actions taken by American Water to complete, the acquisition, on American Water's operations, strategy, guidance, expectations and plans with respect to its regulated businesses (considered individually or together as a whole), its current or future capital expenditures, its current and future debt and equity capital needs, dividends, earnings (including earnings per share), growth, future regulatory outcomes, expectations with respect to rate base growth, and other financial and operational goals, plans, estimates and projections; and (iii) any requirement by American Water to pay a termination fee in the event the closing does not occur; risks and uncertainties following the completion of the sale of American Water's former Homeowner Services Group business, including: American Water's ability to receive amounts due, payable and owing under the amended secured seller note when due; and its ability to redeploy successfully and timely the net proceeds of such transaction into its regulated businesses; risks and uncertainties associated with contracting with the U.S. government, including ongoing compliance with applicable government procurement, security and cybersecurity regulations; cost overruns relating to improvements in or the expansion of American Water's operations; American Water's ability to successfully develop and implement new technologies and to protect related intellectual property; American Water's ability to maintain safe work sites; American Water's exposure to liabilities related to environmental laws and regulations, including those enacted or adopted and under consideration, and the substances related thereto, including without limitation copper, lead and galvanized steel, PFAS and other contaminants of emerging concern, and similar matters resulting from, among other things, water and wastewater service provided to customers; the ability of energy providers, state governments and other third parties to achieve or fulfill their greenhouse gas emission reduction goals, including without limitation through stated renewable portfolio standards and carbon transition plans; the inability of the forward purchasers or underwriters to perform their obligations with respect to this offering and other disruptions or other changes in general economic, political, business and financial market conditions; access to sufficient debt and/or equity capital on satisfactory terms and as needed to support operations and capital expenditures; fluctuations in inflation or interest rates, and American Water's ability to address or mitigate the impacts thereof; the ability to comply with affirmative or negative covenants in the current or future indebtedness of American Water or any of its subsidiaries, or the issuance of new or modified credit ratings or outlooks by credit rating agencies with respect to American Water or any of its subsidiaries (or any current or future indebtedness thereof), which could increase financing costs or funding requirements and affect American Water's or its subsidiaries' ability to issue, repay or redeem debt, pay dividends or make distributions; fluctuations in the value of, or assumptions and estimates related to, its benefit plan assets and liabilities, including with respect to its pension and other post-retirement benefit plans, that could increase expenses and plan funding requirements; changes in federal or state general, income and other tax laws, including (i) future significant tax legislation or regulations (including without limitation impacts related to the Corporate Alternative Minimum Tax), and (ii) the availability of, or American Water's compliance with, the terms of applicable tax credits and tax abatement programs; migration of customers into or out of its service territories and changes in water and energy consumption resulting therefrom; the use by municipalities of the power of eminent domain or other authority to condemn the systems of one or more of American Water's utility subsidiaries, including without limitation litigation and other proceedings with respect to the water system assets of its California subsidiary located in Monterey, California, or the assertion by private landowners of similar rights against such utility subsidiaries; any difficulty or inability to obtain insurance for American Water, its inability to obtain insurance at acceptable rates and on acceptable terms and conditions, or its inability to obtain reimbursement under existing or future insurance programs and coverages for any losses sustained; the incurrence of impairment charges, changes in fair value and other adjustments related to American Water's goodwill or the value of its other assets; labor actions, including work stoppages and strikes; American Water's ability to retain and attract highly qualified and skilled employees and talent; civil disturbances or unrest, or terrorist threats or acts, or public apprehension about future disturbances, unrest, or terrorist threats or acts; and the impact of new, and changes to existing, accounting standards. These forward-looking statements are qualified by, and should be read together with, the risks and uncertainties set forth above, and the risk factors included in American Water's annual, quarterly and other SEC filings, and readers should refer to such risks, uncertainties and risk factors in evaluating such forward-looking statements. Any forward-looking statements American Water makes shall speak only as of the date of this press release. American Water does not have any obligation, and specifically disclaims any undertaking or intention, to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or otherwise. New factors emerge from time to time, and it is not possible for American Water to predict all such factors. Furthermore, it may not be possible to assess the impact of any such factor on American Water's businesses, either viewed independently or together, or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. The factors set forth above in this press release should not be construed as exhaustive. AWK-IR
Business Wire
27 minutes ago
- Business Wire
agilon health, inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President, CEO, and Board Director Steven Sell stepped down from his positions. The Company added, 'In a separate press release, the Company today also issued its second quarter 2025 earnings results. As part of that announcement, and in conjunction with this leadership transition, the Company is withdrawing its previous full year 2025 earnings guidance.' Based on this news, shares of Agilon fell more than 27% in after hours trading following the Company's release. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
